Savannah Demko is a Senior Editorial Features Manager at Healio. With a strong background in medical journalism since 2016, she specializes in hematology/oncology, rheumatology, and immunology, focusing on the latest advancements in immunotherapy and other medical specialties. Savannah's work has been featured in Healio, where she continues to contribute to the field of medical publishing.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Chicago, United States (Local)
Not enough data
Savannah Demko's coverage mainly focuses on healthcare and pharmaceuticals, with a specific emphasis on hemophilia, gene therapy, and sarcoma. Her articles frequently include cited data and expert commentary.
If you aim to reach out effectively, consider providing well-researched data or studies related to advancements in hemophilia treatment or gene therapy. Experts who can offer insightful commentary on the developments in these fields would likely gain her attention.
Savannah does not have a specified geographic focus but appears to cover global healthcare topics. Therefore, pitches should emphasize international relevance rather than regional specifics.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Minna Kohler, Savannah Demko
CHICAGO — Vagus nerve-mediated neuroimmune modulation by electrical stimulation using an implantable device was well-tolerated and had durable efficacy through 12-months in adults with rheumatoid arthritis, according to results from the RESET-RA study presented at ACR Convergence 2025.
By: Savannah Demko, Minna Kohler
CHICAGO — Neuroimmune modulation inhibited progression of structural damage in patients with rheumatoid arthritis who had inadequate response or intolerance to DMARD therapy, according to data presented at ACR Convergence 2025.
By: Savannah Demko, Minna Kohler
CHICAGO — Neuroimmune modulation could be an “emerging therapeutic approach” for patients with rheumatoid arthritis who had incomplete response or intolerance to anti-TNF therapy, according to Minna Kohler, MD, RhMSUS.
By: Savannah Demko, Anat Loewenstein, Christine Klimanskis
Video Player is loading. Play Video Play Mute Current Time Duration Loaded Stream Type LIVE
By: Vivienne S. Hau, Savannah Demko, Christine Klimanskis
Video Player is loading. Play Video Play Mute Current Time Duration Loaded Stream Type LIVE
By: Christine Klimanskis, Vivienne S. Hau, Savannah Demko
Video Player is loading. Play Video Play Mute Current Time Duration Loaded Stream Type LIVE
By: Vivienne S. Hau, Savannah Demko
In this video, Vivienne S. Hau, MD, PhD, discussed a session presented at the American Society of Retina Specialists annual meeting on emerging durable treatments for wet age-related macular degeneration.“This was really interesting because we talked about several different types of mechanisms, the safety and efficacy, and the long-term duration and how we’re moving beyond basically
By: Vivienne S. Hau, Savannah Demko, Christine Klimanskis
Video Player is loading. Play Video Play Mute Current Time Duration Loaded Stream Type LIVE
By: Vivienne S. Hau, Savannah Demko, Christine Klimanskis
Video Player is loading. Play Video Play Mute Current Time Duration Loaded Stream Type LIVE
By: Vivienne S. Hau, Savannah Demko
Major topics of discussion at this year’s American Society of Retina Specialists annual meeting included real-world data on the treatment of geographic atrophy in dry age-related macular degeneration.“This was huge this year because now we actually have medications that can slow down the progression of geographic atrophy and macular degeneration,” Vivienne S. Hau, MD, PhD, of
